Found: 12
Select item for more details and to access through your institution.
Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients
- Published in:
- Neuroendocrinology, 2021, v. 111, n. 9, p. 863, doi. 10.1159/000511662
- By:
- Publication type:
- Article
Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma.
- Published in:
- Neuroendocrinology, 2019, v. 109, n. 4, p. 287, doi. 10.1159/000499497
- By:
- Publication type:
- Article
Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms.
- Published in:
- Neuroendocrinology, 2019, v. 108, n. 1, p. 7, doi. 10.1159/000493980
- By:
- Publication type:
- Article
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): Prevalence, clinicopathological characteristics and survival outcome in a cohort of 311 patients with well‐differentiated lung neuroendocrine tumours.
- Published in:
- Journal of Neuroendocrinology, 2022, v. 34, n. 10, p. 1, doi. 10.1111/jne.13184
- By:
- Publication type:
- Article
Distinguishing Cushing's disease from the ectopic ACTH syndrome: Needles in a haystack or hiding in plain sight?
- Published in:
- Journal of Neuroendocrinology, 2022, v. 34, n. 8, p. 1, doi. 10.1111/jne.13137
- By:
- Publication type:
- Article
The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials.
- Published in:
- Journal of Neuroendocrinology, 2021, v. 33, n. 9, p. 1, doi. 10.1111/jne.13015
- By:
- Publication type:
- Article
The Clinical Utility of the NETest in Patients with Small Intestinal Neuroendocrine Neoplasms (Si-NENs): A "Real-Life" Study.
- Published in:
- Cancers, 2024, v. 16, n. 14, p. 2506, doi. 10.3390/cancers16142506
- By:
- Publication type:
- Article
Dual [<sup>68</sup>Ga]DOTATATE and [<sup>18</sup>F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms.
- Published in:
- Endocrine (1355008X), 2020, v. 67, n. 1, p. 233, doi. 10.1007/s12020-019-02086-6
- By:
- Publication type:
- Article
<sup>177</sup>Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 11, p. 3582, doi. 10.1007/s00259-021-05332-0
- By:
- Publication type:
- Article
Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
- Published in:
- PLoS ONE, 2018, v. 13, n. 1, p. 1, doi. 10.1371/journal.pone.0191455
- By:
- Publication type:
- Article